IQVIA’s (NYSE:IQV) Q3 2026: beats on revenue
IQVIA reported Q3 2026 revenue of $4.43 billion, beating estimates by 1.5% and growing 8% year-on-year. Adjusted EPS was $3.34, a 2% beat. The company raised full-year revenue guidance to $17.43 billion and adjusted EPS guidance to $12.95. Operating margin remained steady at 12.9%, but free cash flow margin declined to 15.1%.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise may attract growth‑oriented investors and could lift the broader health‑tech space.
Market read
Strong Q3 results and raised guidance provide a clear catalyst for IQV stock and may influence sector sentiment.
What to watch
Guidance lift is modest; macro‑economic headwinds could temper upside.
Background
IQVIA is a leading provider of healthcare data, analytics, and technology solutions.
Ticker impact
IQVIA reported Q3 2026 results beating revenue and EPS estimates and raised full-year guidance.
likely upward move as market prices in the beat and guidance raise
Both revenue and EPS beat consensus and guidance was lifted, which typically drives buying.
Market effects
Health‑care services sector may see modest rally on stronger-than-expected demand.
U.S. markets may open higher on the back of the earnings beat.
Limited to investors tracking health‑care data and analytics firms.
Counterpoint
If the beat is already priced in, the stock could face short‑term profit‑taking.
Key entities
- CompanyIQVIA
Healthcare data and analytics firm.
